Istari Oncology, is a clinical-stage biotechnology company focused on novel immuno-oncology and immunotherapy platforms for the treatment of glioblastoma and a wide variety of tumors.

Istari was founded by Darell Bigner, MD, and Matthias Gromeier, MD, of Duke University Medical Center. In 2016, Duke University licensed a broad range of patents and patent applications to Istari Oncology and provided access to additional intellectual property created at Duke to continue clinical and commercial development of these technologies.